THE CURRENT STATUS OF MALE HYPOGONADISM IN CAN THO CITY
Main Article Content
Abstract
Background: Male hypogonadism is related to the decline in testicular function, androgen production, and sperm production. Currently, questionnaires such as ADAM and ANDROTEST are used to screen for male hypogonadism. ADAM has high sensitivity (90.12%) but low specificity (41.3%), while ANDROTEST has lower sensitivity (71%) but higher specificity (65%). Objectives: The current status of male hypogonadism and the investigation of factors associated with male hypogonadism. Materials and methods: A cross-sectional study was conducted on 1812 males aged ≥ 16 years from January 2024 to the end of March 2025 in Can Tho City. Results: The mean age was 46.16 ± 14.94 years, with 38.7% of patients diagnosed with hypogonadism according to the ADAM scale and 18.8% according to the ANDROTEST scale. A statistically significant association (p < 0.05) was found between male hypogonadism and the following factors: erectile dysfunction, waist circumference > 90 cm, body mass index ≥ 23 kg/m², diabetes mellitus, dyslipidemia. Conclusion: Male hypogonadism is significantly associated with factors such as waist circumference, body mass index, diabetes mellitus, and dyslipidemia, with the prevalence of male hypogonadism being 38.7% according to the ADAM questionnaire and 18.8% according to the ANDROTEST questionnaire in Can Tho City.
Keywords
male hypogonadism, androgen deficiency of the aging male (ADAM), International Index of Erectile Function (IIEF), ANDROTEST Screening Questionnaire
Article Details
References
2. Naz S, Mandhan N, Shankar P, Raj K, Memon S. Sensitivity, Specificity and Accuracy of Androgen Deficiency in Ageing Male (ADAM) Questionnaire for the Clinical Detection of Androgen Deficiency in the Male Population in Pakistan. Cureus. 2020. 12(11), 11788, doi: 10.7759/cureus.11788.
3. Corona G, Mannucci E, Petrone L, Balercia G, Fisher AD, et al. ANDROTEST: a structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med. 2006. 3(4), 706-715, doi: 10.1111/j.1743-6109.2006.00262.x.
4. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007. 92(11), 4241-4247, doi: 10.1210/jc.2007-1245.
5. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 1999. 54(2), 346-351, doi: 10.1016/s0090-4295(99)00099-0.
6. Lowy M, Ramanathan V. Erectile dysfunction: causes, assessment and management options. Aust Prescr. 2022. 45(5), 159-161, doi: 10.18773/austprescr.2022.051.
7. Huang M.Y, Parker G, Zarotsky V, Carman W, Morgentaler A, et al. PIH7. The Prevalence, Incidence, And Treatment Rates Of Hypogonadism In Men Across Geographies: A Systematic Literature Review. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2013. 16(3), A70-A71, doi: 10.1016/j.jval.2013.03.315.
8. Urgie NT, Surur MO, Nigussie S, Worku Yigazu B, Bobosha K, et al. Hypogonadism and associated factors among male Leprosy patients. PLoS Negl Trop Dis. 2024. 18(8), e0012374, doi: 10.1371/journal.pntd.0012374.
9. Düğer H. The prevalence of hypogonadism in male patients with type 2 diabetes mellitus and clinically relevant factors. J Health Sci Med / JHSM. 2024. 7(1), 53-57, doi:10.32322/jhsm.1387621.
10. Dhindsa S, Champion C, Deol E, Lui M, Campbell R, et al. Association of Male Hypogonadism With Risk of Hospitalization for COVID-19. JAMA Netw Open. 2022. 5(9), e2229747, doi:
10.1001/jamanetworkopen.2022.29747.
11. Muraleedharan V, Jones TH. Testosterone and the metabolic syndrome. Ther Adv Endocrinol Metab. 2010. 1(5), 207-23, doi: 10.1177/2042018810390258.